Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
Go back to Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review| TIBCO Software, Inc. (NYSE: IBX) | Delayed: 25.97 +2.00 (8.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.97 | 52 Week High | $0.90 | |||
| Open | $25.54 | 52 Week Low | $0.48 | |||
| Day High | $26.79 | P/E | 118.05 | |||
| Day Low | $24.48 | EPS | $0.22 | |||
| Volume | 1,796,079 | |||||
